Compare AngloGold Ashanti Limited (AU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AngloGold Ashanti Limited vs Sana Biotechnology Inc — how do they compare? AngloGold Ashanti Limited trades at $79.56 (market cap $40.62B), while Sana Biotechnology Inc trades at $3.58 (market cap $994.89M). The key difference: AngloGold Ashanti Limited is far larger — about 40.8× Sana Biotechnology Inc's market cap, and AngloGold Ashanti Limited pays a 5.73% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AU | SANA | |
|---|---|---|
Market Cap | $40.62B | $994.89M |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $5.92 |
52-Week Low | $46.25 | $2.68 |
Enterprise Value | $39.75B | $969.08M |
Dividend Yield | 5.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $79.76, down 2.85% amid bearish technical signals. The stock shows strong fundamentals with 2025 revenue growth to $9.89B and net income of $2.64B, supported by a 31.11% net margin. Recent Q1 2026 earnings beat expectations at $2.52 EPS versus $2.27 forecast. Analyst consensus remains positive with a $118.60 price target, though technical indicators show selling pressure with support at $77-79 levels.
The outlook remains favorable given robust cash flow growth and geographic diversification, but faces risks from gold price volatility and recent technical weakness. With 64% analyst buy ratings and significant upside to price targets, the stock presents value opportunity for patient investors despite near-term bearish momentum.
SANA Biotechnology trades at $3.64, down 5.45% over 24 hours, with a bullish technical signal and strong analyst support (81.82% buy ratings). Recent news highlights clinical progress, including NEJM publications and conference presentations, but financials show significant losses with a net income of -$244.17M in 2025 and negative cash flows.
The outlook is mixed: strong scientific momentum and Wall Street optimism contrast with deep financial losses and high burn rate. Key risks include funding needs and clinical trial outcomes, while potential upside hinges on successful product development and partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AngloGold Ashanti Limited
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
